Sustained impairment of pituitary and testicular function in prostatic cancer patients treated with a depot form of a GnRH agonist

Horm Res. 1988;30(1):22-5. doi: 10.1159/000181020.

Abstract

Seven patients suffering from prostatic cancer were treated with a slow-release D-Trp-6-LHRH preparation for a period of 24-32 months. LH, FSH, PRL and testosterone levels were evaluated before and at the end of treatment and then 40 days later. Baseline and GnRH-, TRH-, and HCG-stimulated hormonal values decreased after treatment. The possibility that a long-term treatment with GnRH analogues induces a sustained suppression of pituitary and testicular function is suggested.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Delayed-Action Preparations
  • Follicle Stimulating Hormone / blood*
  • Gonadotropin-Releasing Hormone / administration & dosage
  • Gonadotropin-Releasing Hormone / analogs & derivatives*
  • Gonadotropin-Releasing Hormone / therapeutic use
  • Humans
  • Luteinizing Hormone / blood*
  • Male
  • Middle Aged
  • Prolactin / blood*
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / physiopathology
  • Testosterone / blood*
  • Triptorelin Pamoate

Substances

  • Antineoplastic Agents
  • Delayed-Action Preparations
  • Triptorelin Pamoate
  • Gonadotropin-Releasing Hormone
  • Testosterone
  • Prolactin
  • Luteinizing Hormone
  • Follicle Stimulating Hormone